This is a working overview of ACTH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
== Regulation of TIMP expression == Transcription of this gene is highly inducible in response to many cytokines and hormones. In addition, the expression from some but not all inactive X chromosomes suggests that this gene inactivation is polymorphic in human females. This gene is located within intron 6 of the synapsin I gene and is transcribed in the opposite direction. In adrenocortical cells the trophic hormone ACTH induces expression of TIMP-1 and the increase in TIMP expression is also associated with decreased collagenase activity. Increased expression of TIMP1 has been found to be associated with worse prognosis of various tumors, such as laryngeal carcinoma or melanoma.
Even though the half-lives of these nuclei are very short (on the order of seconds), the very existence of elements heavier than rutherfordium is indicative of stabilizing effects thought to be caused by closed shells; a model not considering such effects would forbid the existence of these elements due to rapid spontaneous fission. Flerovium, with the expected magic 114 protons, was first synthesized in 1998 at the Joint Institute for Nuclear Research in Dubna, Russia, by a group of physicists led by Yuri Oganessian. A single atom of element 114 was detected, with a lifetime of 30.4 seconds, and its decay products had half-lives measurable in minutes. Because the produced nuclei underwent alpha decay rather than fission, and the half-lives were several orders of magnitude longer than those previously predicted or observed for superheavy elements, this event was seen as a "textbook example" of a decay chain characteristic of the island of stability, providing strong evidence for the existence of the island of stability in this region. Even though the original 1998 chain was not observed again, and its assignment remains uncertain, further successful experiments in the next two decades led to the discovery of all elements up to oganesson, whose half-lives were found to exceed initially predicted values; these decay properties further support the presence of the island of stability.
=== Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies === The Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies (CAPAS) is a National Institute on Aging (NIA)-funded research center dedicated to advancing the understanding of Alzheimer's disease and related dementias (AD/ADRD) through multidisciplinary population science. The Center brings together investigators from epidemiology, demography, sociology, economics, psychology, public health, geriatrics, neurology, and biomedical sciences to examine the complex biological, behavioral, environmental, and social factors that influence cognitive aging and dementia risk. By integrating diverse scientific disciplines, CAPAS seeks to identify modifiable determinants of cognitive decline and generate evidence that informs strategies for preventing dementia, reducing disability, and promoting healthy cognitive aging across the lifespan. The Center's research focuses on understanding how demographic characteristics, socioeconomic conditions, education, health behaviors, chronic disease, healthcare access, neighborhood environments, and social relationships interact with biological aging to influence the development and progression of Alzheimer's disease and related dementias. Investigators utilize large national and international longitudinal cohort studies, population surveys, administrative datasets, electronic health records, and advanced statistical modeling to examine risk and protective factors affecting cognitive health.
1808: Anna Sundström began assisting Jacob Berzelius in his laboratory, becoming one of the first Swedish women chemists. 1809: Italian pharmacist Sabina Baldoncelli earned her university degree in pharmacy but was allowed to work only in the Italian orphanage where she resided. 1815: English archaeologist and antiquarian Lady Hester Stanhope used a medieval Italian manuscript to locate a promising archaeological site in Ashkelon, becoming the first archaeologist to begin an excavation in the Palestinian region. It was one of the earliest examples of the use of textual sources in field archaeology. 1816: French mathematician and physicist Sophie Germain became the first woman to win a prize from the Paris Academy of Sciences for her work on elasticity theory. 1823: English palaeontologist and fossil collector Mary Anning discovered the first complete Plesiosaurus. 1831: Italian botanist Elisabetta Fiorini Mazzanti published her best-known work Specimen Bryologiae Romanae. 1830–1837: Belgian botanist Marie-Anne Libert published her four-volume Plantae cryptogamicae des Ardennes, a collection of 400 species of mosses, ferns, lichen, algae and fungi from the Ardennes region. Her contributions to systemic cryptogamic studies were formally recognized by Prussian king Friedrich Wilhelm III, and Libert received a gold medal of merit. 1832: French marine biologist Jeanne Villepreux-Power invented the first glass aquarium, using it to assist in her scientific observations of Argonauta argo.
Sources: en.wikipedia.org
=== Differential Diagnosis === While Kwashiorkor is primarily characterized by edema, growth failure, and dermatitis, it can sometimes be misdiagnosed as Acrodermatitis Enteropathica (AE), as both conditions present with similar dermatological symptoms. However, AE is caused by zinc deficiency, not protein deficiency, and is associated with a significant decrease in serum zinc levels. Unlike kwashiorkor, which is diagnosed based on clinical signs like edema and low serum albumin levels, AE requires additional diagnostic tests, such as zinc uptake tests and genetic screening, to differentiate it from other disorders with similar symptoms. Therefore, while both conditions can present with dermatitis, the underlying etiology helps distinguish the two.
== Physiology == MC5R is necessary for normal sebum production. Stimulation of MC5R promotes fatty acid oxidation in skeletal muscle and lipolysis in adipocytes. MC5R is essential for erythrocyte differentiation. MC5R is involved in inflammation. MC5R helps maintain thermal homeostasis. Stimulation of the MC5R in skeletal muscle causes glucose uptake. In vitro, MC5R agonism is cardioprotective and kidney protective. MC5R is expressed in the brain at different levels depending on physical activity.
The presence of breast implants currently presents no contraindication to breast feeding, and there is no evidence to support that the practice may present health issues to a breastfeeding infant. Women with breast implants may have functional breast-feeding difficulties; mammoplasty procedures that feature periareolar incisions are especially likely to cause breastfeeding difficulties. Surgery may also damage the lactiferous ducts and the nerves in the nipple-areola area. Functional breastfeeding difficulties arise if the surgeon cut the milk ducts or the major nerves innervating the breast, or if the milk glands were otherwise damaged. Milk duct and nerve damage are more common if the incisions cut tissue near the nipple. The milk glands are most likely to be affected by subglandular implants and by large-sized breast implants, which pinch the lactiferous ducts and impede milk flow. Small-sized breast implants and submuscular implantation cause fewer breast-function problems; however, it is impossible to predict whether a woman who undergoes breast augmentation will be able to successfully breast feed since some women are able to breast-feed after periareolar incisions and subglandular placement and some are not able to after augmentation using submuscular and other types of surgical incisions.
== Selectivity == While serine/threonine kinases all phosphorylate serine or threonine residues in their substrates, they select specific residues to phosphorylate on the basis of residues that flank the phosphoacceptor site, which together comprise the consensus sequence. Since the consensus sequence residues of a target substrate only make contact with several key amino acids within the catalytic cleft of the kinase (usually through hydrophobic forces and ionic bonds), a kinase is usually not specific to a single substrate, but instead can phosphorylate a whole "substrate family" which share common recognition sequences. While the catalytic domain of these kinases is highly conserved, the sequence variation that is observed in the kinome (the subset of genes in the genome that encode kinases) provides for recognition of distinct substrates. Many kinases are inhibited by a pseudosubstrate that binds to the kinase like a real substrate but lacks the amino acid to be phosphorylated. When the pseudosubstrate is removed, the kinase can perform its normal function.
=== Sugar ring modifications === Another modification that is useful for medical applications of oligonucleotides is 2' sugar modifications. Modifying the 2' position sugar increases the effectiveness of oligonucleotides by enhancing the target binding capabilities of oligonucleotides, specifically in antisense oligonucleotides therapies. They also decrease non specific protein binding, increasing the accuracy of targeting specific proteins. Two of the most commonly used modifications are 2'-O-methyl and the 2'-O-methoxyethyl. Fluorescent modifications on the nucleobase was also reported.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.